Background: Advances in next-generation sequencing technologies are changing the ways cancer diagnosis and treatment, which leads to a new branch of precision medicine: "Precision Oncology". This study aims to deliver a structured overview to carry out a bibliometric analysis of precision oncology research over the past 10 years retrospectively.Methods: Bibliometric methods including clustering analysis and co-occurrence visualized study were conducted based on publications of academic databases Web of Science Main Collection from 1st January 2012, to 31st December 2021. This study analyzed the information about related research outputs, countries, institutions, authors, cited papers, and hot topics.Results: 7163 papers related to precision oncology were identified. Since 2014, the number of articles has proliferated, and oncology precision has attracted significant attention from scholars worldwide in recent years. The USA leads the research in this field, and the League of European Research Universities is the primary research institution. Research institutions from Asia paid more attention to this field through high-level international cooperation. Besides, there are still many issues expected to be explored and evaluated correctly. Such as the considerable uncertainty that pharmacogenomic methods have no significant influence on patient outcomes.Conclusions: Precision oncology serves as an essential method in clinical treatment, and is closely related to biological study, including biochemistry, molecular and genetics, advanced technology, and pharmacology discovery. The future research prospect would be the broad involvement of social participation and global cooperation in oncology precision research to acquire better results via the balance of technology and public health policy.Abbreviations: EGFR = epidermal growth factor receptor, HR = hazard ratio, TP = total publications.
Background Limited research has been conducted on the association between preconception exposure to ambient particulate matter (PM) and hypothyroidism. This study aimed to investigate the relationship between preconception PM exposure and hypothyroidism. Methods A retrospective case–control study at China-Japan Friendship Hospital was performed. Fine particulate matter (PM2.5) and inhalable particulate matter (PM10) were obtained from the China High Air Pollution Dataset. Buffer analysis methods were used to calculate the exposure of pregnant women to PM in a circular area of 250, 500, and 750 m in diameter at preconception and in early pregnancy. Logistic regression models were used to assess the relationship between PM and hypothyroidism. Odd ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the effect of PM on the risk of hypothyroidism. Results A total of 3,180 participants were studied, and they comprised 795 hypothyroid patients and 2,385 matched controls. The mean age was 31.01 years (standard deviation: 3.66) in the control group and 31.16 years (standard deviation: 3.71) in the case group. Logistic regression analysis showed that exposure to PM2.5 and PM10 in the 60-day period before the last menstrual period month (LMPM), 30-day period before the LMPM, and LMP, across all distance buffers, was associated with an increased risk of hypothyroidism (all P < 0.05). The most pronounced effect was observed during the LMPM, with PM2.5 (OR: 1.137, 95% CI: 1.096–1.180) and PM10 (OR: 1.098, 95% CI: 1.067–1.130) in the 250-m buffer. Subgroup analysis in the Changping District yielded consistent results with the main analysis. Conclusion Our study shows that preconception PM2.5 and PM10 exposure increases the risk of hypothyroidism during pregnancy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.